NeoGenomics NEO Reportable Segment — Sales and marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about NeoGenomics's reportable segment — sales and marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NeoGenomics's reportable segment — sales and marketing?
- NeoGenomics (NEO) reported reportable segment — sales and marketing of $23.48M in Q1 2026.
- How has NeoGenomics's reportable segment — sales and marketing changed year-over-year?
- NeoGenomics's reportable segment — sales and marketing increased by 8.1% year-over-year, from $21.71M to $23.48M.
- What is the long-term trend for NeoGenomics's reportable segment — sales and marketing?
- Over 3 years (2022 to 2025), NeoGenomics's reportable segment — sales and marketing has grown at a 9.7% compound annual growth rate (CAGR), from $67.32M to $88.83M.
- What does reportable segment — sales and marketing mean?
- Costs incurred to promote services, acquire new clients, and maintain relationships with healthcare providers and pharmaceutical partners. This metric indicates the segment's investment in market penetration and customer acquisition efficiency.